文献速递白血病

Talacotuzumab联合地西他滨对比地西他滨单药治疗不适合化疗的急性髓系白血病:多中心随机2/3期研究

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
PubMed 文献 · Leukemia · 2020-03-16

该多中心2/3期研究在不适合强化化疗的老年急性髓系白血病患者中,先确定talacotuzumab联合地西他滨的II期推荐剂量为9 mg/kg,随后随机比较联合治疗与地西他滨单药。结果显示联合治疗未改善完全缓解率或总生存,独立数据监察委员会建议提前终止入组并停用talacotuzumab。

要点

  • talacotuzumab联合地西他滨的II期推荐剂量为9 mg/kg。
  • 联合治疗组完全缓解率15%,单药组11%,差异无统计学意义。
  • 联合治疗未改善总生存,研究因无效提前终止。

核心结论

  • talacotuzumab联合地西他滨在不适合化疗的急性髓系白血病患者中未显示优于地西他滨单药的疗效。

研究设计与样本

  • 多中心2/3期研究,Part A确定II期推荐剂量,Part B为开放标签随机对照比较联合治疗与地西他滨单药。

主要发现

  • Part A确认talacotuzumab的II期推荐剂量为9 mg/kg。
  • Part B中联合治疗组完全缓解为12/80(15%),单药组为9/82(11%),比值比1.4(95%CI 0.6-3.6),p=0.44。
  • 中位总生存联合治疗组为5.36个月(95%CI 4.27-7.95),单药组为7.26个月(95%CI 6.47-8.64),风险比1.04(95%CI 0.79-1.37),p=0.78。

关键数值与推荐

  • II期推荐剂量为talacotuzumab 9 mg/kg。
  • 完全缓解率联合组15%对比单药组11%,差异无统计学意义。
  • 中位总生存联合组5.36个月对比单药组7.26个月,差异无统计学意义。

临床怎么用

  • 对于不适合强化化疗的老年急性髓系白血病患者,不推荐使用talacotuzumab联合地西他滨方案。
  • 地西他滨单药仍是该人群的可行治疗选择之一。

局限性

  • 研究因联合治疗无效被独立数据监察委员会建议提前终止入组和停用talacotuzumab治疗。
  • 结果基于2018年1月25日数据库锁定时的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicenter, phase 2/3 study was initiated to determine the recommended phase 2 dose (RP2D) of talacotuzumab (Part A) followed by an open-label, randomized comparison of talacotuzumab in combination with decitabine versus decitabine alone to assess achievement of complete response (CR) and overall survival (OS) in Part B. Ten patients were enrolled in Part A and 316 in Part B; the results presented here are based on a database lock on January 25, 2018. Part A confirmed the RP2D of talacotuzumab to be 9 mg/kg. In Part B, CR was achieved in 12/80 (15%) patients receiving combination therapy and in 9/82 (11%) patients receiving decitabine alone (odds ratio: 1.4; 95% confidence interval [CI]: 0.6-3.6; p = 0.44). Median (95% CI) OS was 5.36 (4.27-7.95) months for combination therapy versus 7.26 (6.47-8.64) months for decitabine alone (hazard ratio: 1.04; 95% CI: 0.79-1.37; p = 0.78). Combination therapy showed no improvement in efficacy versus decitabine alone, resulting in the Independent Data Monitoring Committee's recommendation of early termination of enrollment and discontinuation of talacotuzumab treatment.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Montesinos P, Roboz GJ, Bulabois CE, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2020. PMID: 32203138. doi:10.1038/s41375-020-0773-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。